Mira T Keddis1, Hatem Amer2, Nikolay Voskoboev3, Walter K Kremers4, Andrew D Rule5, John C Lieske6. 1. Division of Nephrology and Hypertension, Mayo Clinic, Phoenix, Arizona; and keddis.mira@mayo.edu. 2. Division of Nephrology and Hypertension. 3. Renal Laboratory, Department of Laboratory Medicine and Pathology, and. 4. Department of Health Sciences Research Laboratory, Mayo Clinic, Rochester, Minnesota. 5. Division of Nephrology and Hypertension, Department of Health Sciences Research Laboratory, Mayo Clinic, Rochester, Minnesota. 6. Division of Nephrology and Hypertension, Renal Laboratory, Department of Laboratory Medicine and Pathology, and.
Abstract
BACKGROUND AND OBJECTIVES: eGFR equations have been evaluated in kidney transplant recipients with variable performance. We assessed the performance of the Modification of Diet in Renal Disease equation and the Chronic Kidney Disease Epidemiology Collaboration equations on the basis of creatinine, cystatin C, and both (eGFR creatinine-cystatin C) compared with measured GFR by iothalamate clearance and evaluated their non-GFR determinants and associations across 15 cardiovascular risk factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cross-sectional cohort of 1139 kidney transplant recipients >1 year after transplant was analyzed. eGFR bias, precision, and accuracy (percentage of estimates within 30% of measured GFR) were assessed. Interaction of each cardiovascular risk factor with eGFR relative to measured GFR was determined. RESULTS: Median measured GFR was 55.0 ml/min per 1.73 m(2). eGFR creatinine overestimated measured GFR by 3.1% (percentage of estimates within 30% of measured GFR of 80.4%), and eGFR Modification of Diet in Renal Disease underestimated measured GFR by 2.2% (percentage of estimates within 30% of measured GFR of 80.4%). eGFR cystatin C underestimated measured GFR by -13.7% (percentage of estimates within 30% of measured GFR of 77.1%), and eGFR creatinine-cystatin C underestimated measured GFR by -8.1% (percentage of estimates within 30% of measured GFR of 86.5%). Lower measured GFR associated with older age, women, obesity, longer time after transplant, lower HDL, lower hemoglobin, lower albumin, higher triglycerides, higher proteinuria, and an elevated cardiac troponin T level but did not associate with diabetes, smoking, cardiovascular events, pretransplant dialysis, or hemoglobin A1c. These risk factor associations differed for five risk factors with eGFR creatinine, six risk factors for eGFR Modification of Diet in Renal Disease, ten risk factors for eGFR cystatin C, and four risk factors for eGFR creatinine-cystatin C. CONCLUSIONS: Thus, eGFR creatinine and eGFR creatinine-cystatin C are preferred over eGFR cystatin C in kidney transplant recipients because they are less biased, more accurate, and more consistently reflect the same risk factor associations seen with measured GFR.
BACKGROUND AND OBJECTIVES:eGFR equations have been evaluated in kidney transplant recipients with variable performance. We assessed the performance of the Modification of Diet in Renal Disease equation and the Chronic Kidney Disease Epidemiology Collaboration equations on the basis of creatinine, cystatin C, and both (eGFRcreatinine-cystatin C) compared with measured GFR by iothalamate clearance and evaluated their non-GFR determinants and associations across 15 cardiovascular risk factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cross-sectional cohort of 1139 kidney transplant recipients >1 year after transplant was analyzed. eGFR bias, precision, and accuracy (percentage of estimates within 30% of measured GFR) were assessed. Interaction of each cardiovascular risk factor with eGFR relative to measured GFR was determined. RESULTS: Median measured GFR was 55.0 ml/min per 1.73 m(2). eGFRcreatinine overestimated measured GFR by 3.1% (percentage of estimates within 30% of measured GFR of 80.4%), and eGFR Modification of Diet in Renal Disease underestimated measured GFR by 2.2% (percentage of estimates within 30% of measured GFR of 80.4%). eGFRcystatin C underestimated measured GFR by -13.7% (percentage of estimates within 30% of measured GFR of 77.1%), and eGFRcreatinine-cystatin C underestimated measured GFR by -8.1% (percentage of estimates within 30% of measured GFR of 86.5%). Lower measured GFR associated with older age, women, obesity, longer time after transplant, lower HDL, lower hemoglobin, lower albumin, higher triglycerides, higher proteinuria, and an elevated cardiac troponin T level but did not associate with diabetes, smoking, cardiovascular events, pretransplant dialysis, or hemoglobin A1c. These risk factor associations differed for five risk factors with eGFRcreatinine, six risk factors for eGFR Modification of Diet in Renal Disease, ten risk factors for eGFRcystatin C, and four risk factors for eGFRcreatinine-cystatin C. CONCLUSIONS: Thus, eGFRcreatinine and eGFRcreatinine-cystatin C are preferred over eGFRcystatin C in kidney transplant recipients because they are less biased, more accurate, and more consistently reflect the same risk factor associations seen with measured GFR.
Authors: Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor Journal: Am J Kidney Dis Date: 2011-09-22 Impact factor: 8.860
Authors: Claudio Rigatto; Patrick Parfrey; Robert Foley; Carol Negrijn; Carrie Tribula; John Jeffery Journal: J Am Soc Nephrol Date: 2002-04 Impact factor: 10.121
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Vandana Menon; Michael G Shlipak; Xuelei Wang; Josef Coresh; Tom Greene; Lesley Stevens; John W Kusek; Gerald J Beck; Allan J Collins; Andrew S Levey; Mark J Sarnak Journal: Ann Intern Med Date: 2007-07-03 Impact factor: 25.391
Authors: Shruti Gupta; Sharon G Curhan; Karen J Cruickshanks; Barbara E K Klein; Ronald Klein; Gary C Curhan Journal: Laryngoscope Date: 2019-05-28 Impact factor: 3.325
Authors: Meredith C Foster; Andrew S Levey; Lesley A Inker; Tariq Shafi; Li Fan; Vilmundur Gudnason; Ronit Katz; Gary F Mitchell; Aghogho Okparavero; Runolfur Palsson; Wendy S Post; Michael G Shlipak Journal: Am J Kidney Dis Date: 2017-05-24 Impact factor: 8.860
Authors: M C Foster; D E Weiner; A G Bostom; M A Carpenter; L A Inker; P Jarolim; A A Joseph; J W Kusek; T Pesavento; M A Pfeffer; M Rao; S D Solomon; A S Levey Journal: Am J Transplant Date: 2017-03-30 Impact factor: 8.086
Authors: Jordana B Cohen; Kevin C Eddinger; Kimberly A Forde; Peter L Abt; Deirdre Sawinski Journal: Transplantation Date: 2017-10 Impact factor: 4.939
Authors: Martin Freesmeyer; Falk Gühne; Christian Kühnel; Thomas Opfermann; Thomas Winkens; Anke Werner Journal: Endocrine Date: 2018-11-01 Impact factor: 3.633
Authors: Ahmed Alaini; Deepak Malhotra; Helbert Rondon-Berrios; Christos P Argyropoulos; Zeid J Khitan; Dominic S C Raj; Mark Rohrscheib; Joseph I Shapiro; Antonios H Tzamaloukas Journal: World J Methodol Date: 2017-09-26